http://repository.iphce.org/xmlui/handle/123456789/5312 2026-05-20T18:20:21Z 2026-05-20T18:20:21Z Ethiopian Food and Drug Authority http://repository.iphce.org/xmlui/handle/123456789/5371 2026-03-04T08:15:51Z 2025-01-01T00:00:00Z

Peer-led HIV care and the UNAIDS 90-90-90 treatment targets in Sidama Ethiopia: A cluster randomized trial and economic evaluation of Teach-Test- Link-Trace model (TTLT) trial Ethiopian Food and Drug Authority This study aims to test a new and comprehensive intervention program, never been implemented in Ethiopia before, called the teach-test-link-trace (TTLT) model. The TTLT model involves HIV positive volunteer patients (peer educators) who do HIV counselling (teach), perform HIV testing (test) through HIV self-testing (HIVST) and house-to-house HIV testing (H2H), link HIV positive patients to HIV care (link) and trace lost patients house-to- house (trace).

2025-01-01T00:00:00Z Ethiopian Food and Drug Authority http://repository.iphce.org/xmlui/handle/123456789/5369 2026-03-04T08:16:29Z 2024-01-01T00:00:00Z

A revised Tafenoquine dose to improve radical cure for Vivax malaria -Tafenoquine dosing revised Ethiopian Food and Drug Authority Tafenoquine (TQ), as a single dose regimen, has significant advantages over the longer courses of primaquine (PQ) needed to achieve radical cure of P. vivax. The current data available show that the recommended fixed dose of 300mg TQ in adults is too low and compromised by a lack of weight-based dosing. To ensure maximal impact on health outcomes, the recommended dose for TQ must be optimized for clinical practice. Our study will assess the efficacy and safety of a higher weight based TQ dose regimen.

2024-01-01T00:00:00Z Ethiopian Food and Drug Authority http://repository.iphce.org/xmlui/handle/123456789/5367 2026-03-04T08:16:52Z 2025-01-01T00:00:00Z

Serological testing and treatment for plasmodium vivax malaria: A cluster-randomized trial in Ethiopia Ethiopian Food and Drug Authority The resilience of P. vivax to malaria elimination efforts is due to its ability to form dormant liver stages (hypnozoites) that reactivate weeks to months after the initial infection causing recurrent episodes of malaria (relapses) and ongoing parasite transmission. Relapses account for 60-90% of recurrent infections and clinical cases of P. vivax malaria, and therefore have a significant effect on morbidity at the individual level.

2025-01-01T00:00:00Z Ethiopian Food and Drug Authority http://repository.iphce.org/xmlui/handle/123456789/5366 2026-03-04T08:17:07Z 2025-01-01T00:00:00Z

Pharmacovigilance newsletter Ethiopian Food and Drug Authority The Ethiopian Food and Drug Authority in collaboration with its partners, successfully conducted a four-day Pharmacovigilance Data Management and Analysis Training from July 17–20, 2025, in Adama Town, Ethiopia. The training brought together Pharmacovigilance experts working at the national centre to enhance their technical capacity in monitoring medicine and vaccine safety.

2025-01-01T00:00:00Z